Few worries about GLP-1 drugs spread as quickly as the fear of losing muscle along with fat. A new MRI sub-analysis of the STEP UP trial, which tested semaglutide at 7.2 mg (well above the 2.4 mg Wegovy dose), offers a more nuanced picture than either the alarmists or the optimists would like. It is also a small study, and it needs careful reading.
What the study did
STEP UP was a phase 3b trial that randomised adults with a BMI of 30 or higher to weekly semaglutide 7.2 mg, semaglutide 2.4 mg, or placebo for 72 weeks, alongside a lifestyle intervention. This prespecified secondary analysis, published in Diabetes, Obesity and Metabolism and led by Jøran Hjelmesæth, looked at MRI-measured body composition and a physical function test.
Here is the catch: only 55 of the 1,407 trial participants had a valid baseline scan and were included. Of those, 43 took semaglutide 7.2 mg, 6 took 2.4 mg, and just 6 received placebo. The researchers pooled the two semaglutide arms (n = 49) and compared them with placebo.
The headline findings
Compared with placebo, the pooled semaglutide group showed:
- Total adipose tissue: down 11.1 L (95% CI -16.5 to -5.7; p < 0.0001)
- Visceral adipose tissue: down 1.5 L (p = 0.04)
- Lean body tissue: down 1.7 L (95% CI -4.0 to 0.7; p = 0.16)
- Thigh skeletal muscle volume: down 1.1 L (95% CI -2.3 to 0.1; p = 0.07)
- Thigh muscle fat infiltration: down 0.92 percentage points (p = 0.001)
A sensitivity analysis comparing only the 7.2 mg group with placebo produced similar results. Relative changes also pointed the same way.
Fat loss is clear, muscle volume is not
The fat result is robust, even with a small sample. Losing about 11 liters of adipose tissue relative to placebo, including a measurable drop in visceral fat, is what you would expect from a drug at this dose.
The muscle result is harder to interpret. The thigh muscle volume change did not reach statistical significance, but the p-value of 0.07 and a confidence interval running from -2.3 L to +0.1 L do not amount to evidence of no loss. With only six placebo participants, the study had very little power to detect a difference. "Not significant" here mostly means "we can't tell." The authors' own conclusion says semaglutide was associated with reductions in adipose tissue, skeletal muscle volume and muscle fat infiltration, so they do not claim muscle was spared.
In raw liters, the thigh muscle change was roughly a tenth of the fat change. That comparison should be treated loosely, since these are different tissues and compartments, but it fits what larger body-composition studies of weight-loss drugs have generally suggested: most of the lost mass is fat, with a meaningful minority from lean tissue. Lean tissue also includes water, organs and other non-muscle components, so a drop in lean mass is not automatically a drop in muscle.
The muscle quality signal
The more interesting result is the fall in thigh muscle fat infiltration. Fat deposited within and between muscle fibers is associated with poorer strength and metabolic health, and it tends to accumulate with obesity, insulin resistance and aging. A 0.92 percentage point reduction suggests the muscle that remained was somewhat "cleaner."
Temper the enthusiasm, though. The absolute change is small, and the study did not show that it translates into better strength, mobility or long-term outcomes. Fat infiltration is a proxy marker, not a functional result.
Physical function: reassuring but limited
The functional measure was a 30-second sit-to-stand test. The abstract reports a mean of about 13 repetitions at baseline and 15 at week 72 across the pooled semaglutide and placebo groups. Function did not worsen, which is encouraging. But the test is a coarse measure, it was done in a small subset, and the abstract does not give a clean treatment-versus-placebo contrast. It is not a substitute for strength testing such as grip strength or leg press.
Important caveats
- Tiny comparison group: Six placebo participants make every between-group estimate fragile.
- Subset selection: Participants with valid baseline MRI scans may not represent the full trial population.
- Industry involvement: The trial was a Novo Nordisk study, and several authors are Novo Nordisk employees or shareholders. The MRI analysis involved AMRA Medical, whose authors also disclosed industry ties. This does not invalidate the data, but it is context readers should weigh.
- Secondary analysis: Findings are hypothesis-generating, not definitive.
- Lifestyle component: Participants received lifestyle intervention, so results may not apply to someone taking the drug without support.
The authors themselves call for further research on how weight loss affects muscle composition and function.
Practical takeaways for people on GLP-1s
The study cannot tell you how to protect muscle, since it did not test any muscle-sparing strategy. But it does reinforce a sensible approach based on broader evidence in weight loss and aging:
- Lift weights. Resistance training two to three times a week is the most reliable signal telling your body to keep muscle during a calorie deficit.
- Prioritise protein. Reduced appetite can quietly push protein intake too low. Many clinicians suggest aiming for roughly 1.2 to 1.6 g per kg of body weight daily, adjusted for kidney health and individual needs. Check with your care team.
- Don't rely on the scale. Track waist circumference, strength, and how easily you do daily tasks. If possible, use body composition measurements as well.
- Be careful if you're older or already frail. Those at risk of sarcopenia have less margin for muscle loss and may benefit from closer monitoring.
- Ask about dose and pacing. Faster, larger weight loss means more total tissue loss, which makes protection strategies more important.
The bottom line
This small MRI analysis suggests that high-dose semaglutide mostly removes fat, including visceral fat, while thigh muscle fat infiltration improves and basic physical function holds up. It does not prove muscle is safe. The thigh muscle volume estimate leans toward a loss, and the sample is too small to settle the question. For anyone on a GLP-1 drug, the message is not to panic about muscle, but not to ignore it either. Fat loss can come with a bonus, and the muscle you keep is largely something you have to train and feed.